vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and National Storage Affiliates Trust (NSA). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $187.0M, roughly 1.5× National Storage Affiliates Trust). National Storage Affiliates Trust runs the higher net margin — 12.2% vs -45.7%, a 57.9% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -1.6%). National Storage Affiliates Trust produced more free cash flow last quarter ($299.8M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -2.4%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
National Storage Affiliates Trust is a U.S.-headquartered real estate investment trust focused on self-storage assets. It owns, operates and acquires self-storage facilities across dozens of U.S. states, offering secure storage solutions for residential and commercial customers.
GH vs NSA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $187.0M |
| Net Profit | $-128.5M | $22.9M |
| Gross Margin | 64.6% | 72.5% |
| Operating Margin | -43.0% | 20.2% |
| Net Margin | -45.7% | 12.2% |
| Revenue YoY | 39.4% | -1.6% |
| Net Profit YoY | -15.8% | 36.8% |
| EPS (diluted) | $-1.01 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $187.0M | ||
| Q3 25 | $265.2M | $188.7M | ||
| Q2 25 | $232.1M | $188.8M | ||
| Q1 25 | $203.5M | $188.4M | ||
| Q4 24 | $201.8M | $190.1M | ||
| Q3 24 | $191.5M | $193.6M | ||
| Q2 24 | $177.2M | $190.4M | ||
| Q1 24 | $168.5M | $196.1M |
| Q4 25 | $-128.5M | $22.9M | ||
| Q3 25 | $-92.7M | $18.4M | ||
| Q2 25 | $-99.9M | $19.5M | ||
| Q1 25 | $-95.2M | $13.0M | ||
| Q4 24 | $-111.0M | $16.7M | ||
| Q3 24 | $-107.8M | $18.7M | ||
| Q2 24 | $-102.6M | $17.1M | ||
| Q1 24 | $-115.0M | $59.0M |
| Q4 25 | 64.6% | 72.5% | ||
| Q3 25 | 64.7% | 70.7% | ||
| Q2 25 | 65.0% | 70.5% | ||
| Q1 25 | 63.3% | 70.7% | ||
| Q4 24 | 61.6% | 72.5% | ||
| Q3 24 | 61.1% | 72.8% | ||
| Q2 24 | 59.1% | 72.6% | ||
| Q1 24 | 61.2% | 72.1% |
| Q4 25 | -43.0% | 20.2% | ||
| Q3 25 | -37.3% | 15.8% | ||
| Q2 25 | -45.9% | 16.5% | ||
| Q1 25 | -54.6% | 11.0% | ||
| Q4 24 | -62.4% | 14.5% | ||
| Q3 24 | -61.3% | 15.8% | ||
| Q2 24 | -56.8% | 17.2% | ||
| Q1 24 | -59.2% | 48.9% |
| Q4 25 | -45.7% | 12.2% | ||
| Q3 25 | -35.0% | 9.8% | ||
| Q2 25 | -43.0% | 10.3% | ||
| Q1 25 | -46.8% | 6.9% | ||
| Q4 24 | -55.0% | 8.8% | ||
| Q3 24 | -56.3% | 9.7% | ||
| Q2 24 | -57.9% | 9.0% | ||
| Q1 24 | -68.2% | 30.1% |
| Q4 25 | $-1.01 | $0.23 | ||
| Q3 25 | $-0.74 | $0.17 | ||
| Q2 25 | $-0.80 | $0.19 | ||
| Q1 25 | $-0.77 | $0.10 | ||
| Q4 24 | $-0.90 | $0.19 | ||
| Q3 24 | $-0.88 | $0.18 | ||
| Q2 24 | $-0.84 | $0.16 | ||
| Q1 24 | $-0.94 | $0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $23.3M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $946.0M |
| Total Assets | $2.0B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $23.3M | ||
| Q3 25 | $580.0M | $26.3M | ||
| Q2 25 | $629.1M | $26.1M | ||
| Q1 25 | $698.6M | $19.3M | ||
| Q4 24 | $525.5M | $50.4M | ||
| Q3 24 | $585.0M | $69.9M | ||
| Q2 24 | $933.7M | $59.0M | ||
| Q1 24 | $1.0B | $64.2M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $946.0M | ||
| Q3 25 | $-354.5M | $973.1M | ||
| Q2 25 | $-305.5M | $1.0B | ||
| Q1 25 | $-250.8M | $1.0B | ||
| Q4 24 | $-139.6M | $1.1B | ||
| Q3 24 | $-60.1M | $986.9M | ||
| Q2 24 | $-1.6M | $1.2B | ||
| Q1 24 | $68.3M | $1.3B |
| Q4 25 | $2.0B | $5.1B | ||
| Q3 25 | $1.3B | $5.1B | ||
| Q2 25 | $1.3B | $5.2B | ||
| Q1 25 | $1.3B | $5.3B | ||
| Q4 24 | $1.5B | $5.4B | ||
| Q3 24 | $1.5B | $5.4B | ||
| Q2 24 | $1.6B | $5.3B | ||
| Q1 24 | $1.7B | $5.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $338.5M |
| Free Cash FlowOCF − Capex | $-54.2M | $299.8M |
| FCF MarginFCF / Revenue | -19.3% | 160.3% |
| Capex IntensityCapex / Revenue | 9.9% | 20.7% |
| Cash ConversionOCF / Net Profit | — | 14.79× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $541.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $338.5M | ||
| Q3 25 | $-35.4M | $100.2M | ||
| Q2 25 | $-60.3M | $79.9M | ||
| Q1 25 | $-62.7M | $85.6M | ||
| Q4 24 | $-64.5M | $363.1M | ||
| Q3 24 | $-51.1M | $105.7M | ||
| Q2 24 | $-94.0M | $83.2M | ||
| Q1 24 | $-30.3M | $94.0M |
| Q4 25 | $-54.2M | $299.8M | ||
| Q3 25 | $-45.8M | $88.0M | ||
| Q2 25 | $-65.9M | $73.8M | ||
| Q1 25 | $-67.1M | $79.9M | ||
| Q4 24 | $-83.4M | $344.4M | ||
| Q3 24 | $-55.3M | $101.8M | ||
| Q2 24 | $-99.1M | $79.5M | ||
| Q1 24 | $-37.2M | $88.6M |
| Q4 25 | -19.3% | 160.3% | ||
| Q3 25 | -17.3% | 46.6% | ||
| Q2 25 | -28.4% | 39.1% | ||
| Q1 25 | -33.0% | 42.4% | ||
| Q4 24 | -41.3% | 181.2% | ||
| Q3 24 | -28.9% | 52.6% | ||
| Q2 24 | -55.9% | 41.7% | ||
| Q1 24 | -22.1% | 45.2% |
| Q4 25 | 9.9% | 20.7% | ||
| Q3 25 | 3.9% | 6.5% | ||
| Q2 25 | 2.4% | 3.2% | ||
| Q1 25 | 2.2% | 3.0% | ||
| Q4 24 | 9.4% | 9.8% | ||
| Q3 24 | 2.2% | 2.0% | ||
| Q2 24 | 2.9% | 1.9% | ||
| Q1 24 | 4.1% | 2.7% |
| Q4 25 | — | 14.79× | ||
| Q3 25 | — | 5.44× | ||
| Q2 25 | — | 4.10× | ||
| Q1 25 | — | 6.59× | ||
| Q4 24 | — | 21.70× | ||
| Q3 24 | — | 5.65× | ||
| Q2 24 | — | 4.88× | ||
| Q1 24 | — | 1.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
NSA
Segment breakdown not available.
